<DOC>
	<DOCNO>NCT02063945</DOCNO>
	<brief_summary>Attention Deficit/Hyperactivity Disorder ( ADHD ) one prevalent mental disorder among child adolescent , prevalence 5 % western culture . The basic disorder : inattentive hyperactive/impulsive behavior manifest variety setting cause dysfunction everyday life . ADHD subdivide three sub-types : predominantly inattentive , predominantly hyperactive/impulsive combine type . Common co-morbidities ADHD disruptive disorder ; Oppositional defiant disorder ( ODD ) major one half child combine sub-type ADHD quarter child predominantly inattentive also suffer ODD . Conduct disorder co-morbidity quarter child combine sub-type ADHD . The co-occurrence disorder think negative effect outcome . Methylphenidate ( MPH ) , short long act , mainstay medical treatment ADHD patient , 's efficacy proven variety study . It note MPH also proven beneficial effect child disruptive behavior . For child disruptive disorder Risperidone mainstay medical treatment , proven clinical trial . To best knowledge , `` head head '' study compare two drug treatment pediatric patient ADHD co-morbidity disruptive disorder never do . The investigator aim examine efficacy tolerability MPH vs. Risperidone population . In addition , investigator apply DSM5 's cross cutting symptom measure scale order define unique subset patient . Disruptive mood dysregulation disorder ( DMDD ) new diagnosis late version diagnostic statistical manual ( DSM5 ) . It 's main feature : sever recurrent temper outbursts inconsistent developmental level occur average three time week , outbursts occur least two setting mood outburst irritable angry . This diagnosis differential diagnosis ADHD disruptive disorder .</brief_summary>
	<brief_title>Methylphenidate vs. Risperidone Treatment Children Adolescents With ADHD Disruptive Disorders</brief_title>
	<detailed_description>Secondary study aim : 1 . Comparing efficacy tolerability MPH vs. Risperidone treatment depressive symptom child adolescent ADHD disruptive disorder . 2 . Comparing efficacy tolerability MPH vs. Risperidone treatment manic symptom child adolescent ADHD disruptive disorder . 3 . Comparing impact MPH vs. Risperidone overall every day function child adolescent ADHD disruptive disorder . 4 . Comparing impact MPH vs. Risperidone nighttime sleep child adolescent ADHD disruptive disorder . 5 . Comparing impact MPH vs. Risperidone weight height child adolescent ADHD disruptive disorder . 6 . Assessing overlap diagnosis ADHD disruptive disorder DMDD . 7 . Assessing mood disorder response MPH vs. Risperidone treatment child adolescent ADHD disruptive disorder .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Conduct Disorder</mesh_term>
	<mesh_term>Attention Deficit Disruptive Behavior Disorders</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Clinical diagnosis ADHD ( subtype ) oppositional defiant disorder . Clinical diagnosis ADHD ( subtype ) conduct disorder . Clinical diagnosis specify ADHD oppositional defiant disorder . Clinical diagnosis specify ADHD conduct disorder . Clinical diagnosis unspecified ADHD oppositional defiant disorder . Clinical diagnosis unspecified ADHD conduct disorder . Participant qualify inclusion criterion . Participant willing join study . Epilepsy . Neurogenetic syndrome . Brain tumor . Autism . Participants psychiatric medication change ( dose kind ) last month . Congenital heart , kidney liver defect . Cardiomyopathies . Past hypersensitivity Methylphenidate Risperidone .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>ADHA</keyword>
	<keyword>ODD</keyword>
	<keyword>Conduct disorder</keyword>
	<keyword>Aggression</keyword>
	<keyword>Treatment</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>Risperidone</keyword>
</DOC>